文献速递肝病

2型糖尿病合并高铁蛋白血症患者中MASLD患病率的前瞻性研究

A Prospective Study on the Prevalence of MASLD in Patients With Type 2 Diabetes and Hyperferritinaemia.
PubMed 文献 · Aliment Pharmacol Ther · 2024-11-05

该研究为前瞻性队列的横断面分析,纳入523例50-80岁2型糖尿病无血色病诊断的成人。高铁蛋白血症总体患病率为20.5%(n=107),该组MASLD患病率78.5% vs 62.1%(p=0.001),显著肝纤维化35.5% vs 22.1%(p=0.002)。校正年龄、性别、肥胖及胰岛素使用后,高铁蛋白血症仍为MASLD(OR 2.01;95%CI 1.19-3.39;p=0.009)和显著纤维化(OR 2.33;95%CI 1.43-3.77;p=0.001)的独立预测因素。

要点

  • 2型糖尿病合并高铁蛋白血症者中约80%存在MASLD,超过三分之一存在显著肝纤维化。
  • 高铁蛋白血症组MASLD患病率78.5% vs 无高铁蛋白血症组62.1%(p=0.001)。
  • 高铁蛋白血症组显著肝纤维化患病率35.5% vs 无高铁蛋白血症组22.1%(p=0.002)。

核心结论

  • 2型糖尿病合并高铁蛋白血症者中约80%患有MASLD,超过三分之一存在显著肝纤维化。
  • 高铁蛋白血症可能是2型糖尿病患者MASLD和显著肝纤维化的有用生物标志物。

研究设计与样本

  • 前瞻性队列的横断面分析,纳入523例50-80岁2型糖尿病成人(64%女性),均无血色病诊断。
  • MASLD定义为磁共振成像质子密度脂肪分数(MRI-PDFF)≥5%,显著纤维化定义为磁共振弹性成像(MRE)≥3.0 kPa。
  • 高铁蛋白血症定义为女性血清铁蛋白≥200 ng/mL或男性≥300 ng/mL。

主要发现

  • 平均年龄64.1(±8.1)岁,平均体质指数31.5(±5.9)kg/m2。
  • 高铁蛋白血症总体患病率为20.5%(n=107)。
  • 高铁蛋白血症组MASLD患病率78.5% vs 无高铁蛋白血症组62.1%(p=0.001)。
  • 高铁蛋白血症组显著肝纤维化患病率35.5% vs 无高铁蛋白血症组22.1%(p=0.002)。
  • 校正年龄、性别、肥胖和胰岛素使用后,高铁蛋白血症仍为MASLD(OR 2.01;95%CI 1.19-3.39;p=0.009)和显著肝纤维化(OR 2.33;95%CI 1.43-3.77;p=0.001)的独立预测因素。

关键数值与推荐

  • MASLD定义为MRI-PDFF≥5%,显著肝纤维化定义为MRE≥3.0 kPa。
  • 高铁蛋白血症定义为女性血清铁蛋白≥200 ng/mL或男性≥300 ng/mL。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Elevated levels of serum ferritin, a marker of hepatic iron overload and inflammation, may be associated with metabolic dysfunction-associated steatotic liver disease (MASLD) and hepatic fibrosis. AIM: To determine the prevalence of MASLD and significant hepatic fibrosis among patients with type 2 diabetes mellitus (T2DM) and hyperferritinaemia. METHODS: This is a cross-sectional analysis of a prospective cohort of 523 adults (64% female) aged 50-80 with T2DM and without a diagnosis of haemochromatosis. MASLD and significant fibrosis were defined as magnetic resonance imaging-proton density fat fraction (MRI-PDFF) ≥ 5% and magnetic resonance elastography (MRE) ≥ 3.0 kPa, respectively. Hyperferritinaemia was defined as serum ferritin ≥ 200 ng/mL in females or ≥ 300 ng/mL in males. The primary objective was to determine the prevalence of MASLD and significant fibrosis in hyperferritinaemia. RESULTS: The mean age and body mass index were 64.1 (±8.1) years and 31.5 (±5.9) kg/m2, respectively. The overall prevalence of hyperferritinaemia was 20.5% (n = 107). The prevalence of MASLD (78.5% vs. 62.1%, p = 0.001) and significant fibrosis (35.5% vs. 22.1%, p = 0.002) were higher in participants with hyperferritinaemia than those without. Hyperferritinaemia remained an independent predictor of MASLD (OR 2.01; 95% CI 1.19-3.39; p = 0.009) and significant fibrosis (OR 2.33; CI 1.43-3.77; p = 0.001), even after adjustment for age, sex, obesity and insulin use. CONCLUSION: Approximately 80% of people with hyperferritinaemia and T2DM have MASLD, and more than a third have significant hepatic fibrosis. Hyperferritinaemia may be a useful biomarker for MASLD and significant fibrosis in people with T2DM.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Amangurbanova M, Huang DQ, Noureddin N, et al. A Prospective Study on the Prevalence of MASLD in Patients With Type 2 Diabetes and Hyperferritinaemia. Aliment Pharmacol Ther. 2024. PMID: 39499168. doi:10.1111/apt.18377

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。